Dr SANJAY AGARWALA
Dr Sanjay Agarwala Head-Orthopedics and Traumatology; Director-Professional Services, PD Hinduja Hospital & Medical Research Centre, Mumbai, Maharashtra, India
Dr DHANANJAY GUPTA
Director and Senior Consultant, Orthopedics and Joint Reconstruction and Replacement Surgeon, Fortis Flt Lt Rajan Dhall Hospital, Vasant Kunj, New Delhi, India
Dr SANJAY YADAV
HOD, Dept. of Orthopedics, Aruna Asaf Ali Government Hospital, New Delhi, India
Dr VIJAY GONI
Professor, Dept. of Orthopedic Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab, India
Dr ANIL MEHTANI
Director, Pediatric (Ped) Orthopedics, Max Smart Super Speciality Hospital, Saket, New Delhi; Max Hospital, Gurugram, Haryana; India
Dr KAMAL BACHANI
Director of Orthopedics and Chief Ortho Surgeons, AO Specialty Centre, Malviya Nagar, New Delhi, India
Dr SUBHASH JANGID
Director and HOD, Bone and Joint Institute Speciality: Robotic and Computer Navigated Joint Reconstruction, Fortis Memorial Research Institute, Gurugram, Haryana, India
Dr SUDHIR SETH
Consultant Orthopedic Surgeon and Director at Ortho Point, Chittaranjan Park, New Delhi, India; Associated with Fortis C-DOC, Apollo Spectra, Max Healthcare, National Heart Institute and Rockland Hospital
Dr NIRAD VEGSARKAR
Consultant, Orthopedic Surgeon, Lilavati Hospital, Mumbai, Maharashtra, India
Dr SHUBHRANSHU SHEKHAR MOHANTY
Consultant Orthopedics and Joint Replacement Surgeon, Jaslok, Shushrusha and Nanavati Hospitals, Mumbai, Maharashtra, India
Dr PRADEEP BHOSALE
Senior Director-Robotic Joint Replacement Surgery, Hip and Knee; Nanavati Max Super Speciality Hospital, Mumbai, Maharashtra, India
Dr HEMANT BHANDARI
Joint Replacement, Arthroscopy, Trauma and Orthopedic Surgeon, Bombay Hospital and Medical Research Center, Maharashtra, India
Abstract
Osteoporosis and osteopenia are prevalent conditions in India, particularly among postmenopausal women and the elderly,
leading to increased fracture risks and morbidity. Denosumab, a monoclonal antibody, demonstrates superior efficacy
over other treatments in reducing fracture risk and enhancing bone mineral density (BMD). Clinical trials highlight its
effectiveness in preventing periprosthetic bone loss, improving implant stability, and mitigating femoral head collapse in
various conditions; combination therapies involving denosumab further amplify BMD gains and reduce fracture risk. The
article reviews the efficacy and safety of denosumab in managing osteoporosis, joint replacement therapy, and avascular
necrosis based on a review of clinical evidence and studies. Denosumab emerges as a cornerstone therapy for osteoporosis
management, offering multifaceted benefits in fracture prevention, joint replacement therapy, and avascular necrosis.
